Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity.
Although the application of the concept of a threshold to risk assessment is widespread, there remains little experimental evidence for the existence of thresholds for genotoxic compounds, other than aneugens. The clastogenicity of topoisomerase inhibitors is believed to result from the transient stabilization of the topoisomerase enzyme with DNA during the catalytic cycle. This leads to the formation of a stabilized cleavage complex, which, in turn, may result in the formation of a DNA strand break. This indirect mechanism of clastogenicity is the basis for the concept of threshold for this class of drug. Using micronucleus induction in L5178Y mouse lymphoma cells as a genotoxic end-point, a three pronged approach was used to examine whether the concept of a threshold for clastogenicity could be demonstrated for topoisomerase type II inhibitors in vitro. This involved (i) the study of mechanism (TARDIS assay), (ii) hypothesis testing versus estimation (i.e. scoring up to 10,000 cells/treatment at concentrations immediately above and below the NOEL for micronucleus induction) and (iii) statistical modelling of the concentration-response curves for micronucleus induction. Several topoisomerase type II inhibitors were investigated with varying clastogenic potencies (etoposide = doxorubicin < genistein < ciprofloxacin). Pragmatic thresholds for clastogenicity in L5178Y cells were defined at 0.00236 microg/ml for etoposide, 0.00151 microg/ml for doxorubicin, 1 microg/ml for genistein and 50 microg/ml for ciprofloxacin. In addition, it was demonstrated that etoposide-induced clastogenicity was concentration and time dependent. These results, along with mechanistic data showing that all of the compounds induced concentration-dependent increases in the formation of topoisomerase II stabilized cleavage complexes, provide a weight of evidence to support a threshold concept for clastogenicity with topoisomerase II poisons.
Lynch
Anthony
A
Genetic Toxicology, GlaxoSmithKline, Park Road, Ware SG12 0DP, UK. anthony_m_lynch@gsk.com
Harvey
James
J
Aylott
Michael
M
Nicholas
Emma
E
Burman
Mark
M
Siddiqui
Ayesha
A
Walker
Sarah
S
Rees
Robert
R
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002939:Ciprofloxacin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D005047:Etoposide / Q000494:pharmacology; D019833:Genistein / Q000494:pharmacology; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D009153:Mutagens / Q000494:pharmacology*; D059004:Topoisomerase I Inhibitors
D000890:Anti-Infective Agents; D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D009153:Mutagens; D059004:Topoisomerase I Inhibitors; D002939:Ciprofloxacin; D005047:Etoposide; D004317:Doxorubicin; D019833:Genistein